Startup Durabilityte is positioning implantable engineered cell “factories” as a way to produce therapeutic proteins inside the body, aiming to bypass parts of conventional biologics manufacturing. The platform uses electronic components and on-board sensors to let clinicians monitor and control drug production. The device concept blends biotechnology with implantable electronics to support longer-term, controllable protein delivery rather than fixed-dose regimens. For the biopharma industry, the approach could shift manufacturing and supply-chain constraints, moving some production complexity from large-scale facilities to device-integrated systems. The company’s engineering focus suggests a key differentiator will be the reliability of production control and sensing over time in real clinical conditions.